A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma.
A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma.
This is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with placebo in front-line patients diagnosed with metastatic soft tissue sarcoma (STS).
To be eligible, each patient must meet EACH of the following criteria:
To be eligible, each patient must meet NONE of the following criteria:
Indiannapolis, Indiana, United States
Cinncinnati, Ohio, United States
Bethelehem, Pennsylvania, United States
Ciudad de Buenos Aires, Argentina
Sante Fe, Argentina
Bad Sarrow, Germany
Rozzana, Italy
Gilwice, Poland